NCT03579966 2024-05-07Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)Catalyst Pharmaceuticals, Inc.Phase 3 Terminated63 enrolled 10 charts